BACKGROUND: This study described real-world palbociclib dosing patterns and associated impacts on treatment costs for HR+/HER2- metastatic breast cancer (mBC) in the US. METHODS: Postmenopausal women with HR+/HER2- mBC who initiated palbociclib-based therapy (initiation date = index date) between 02/03/2015 (palbociclib approval) and 02/29/2016, and continuous quarterly activity 1 year before and 6 months after the index date, were identified in the Symphony Health Solutions database. Rates of 1) dose reduction (≥25 mg dose decrease/daily), and 2) reduction or interruption (>60 day gap in continuous drug supply) were assessed using Kaplan-Meier analyses. Drug wastage cost was estimated based on overlapping days between two prescription fills: the last original dose fill and the first reduced dose fill. RESULTS: 1,242 patients initiated palbociclib-based therapy (mean age = 62.7 years, median follow-up = 8.7 months). During the 12-month post-index period, across the first four lines, dose reduction rates were 31.9-33.7% and dose reduction/interruption rates were 63.5-80.9%. A total of 411 (33.1%) patients changed dose, among whom 128 (31.1%) experienced prescription fill overlap (average = 11.1 days). Mean potential drug wastage cost among patients with fill overlap was $5,471. CONCLUSIONS: Most patients receiving palbociclib experienced dose reduction or interruption early in treatment; the associated drug wastage may lead to considerable costs.
BACKGROUND: This study described real-world palbociclib dosing patterns and associated impacts on treatment costs for HR+/HER2- metastatic breast cancer (mBC) in the US. METHODS: Postmenopausal women with HR+/HER2- mBC who initiated palbociclib-based therapy (initiation date = index date) between 02/03/2015 (palbociclib approval) and 02/29/2016, and continuous quarterly activity 1 year before and 6 months after the index date, were identified in the Symphony Health Solutions database. Rates of 1) dose reduction (≥25 mg dose decrease/daily), and 2) reduction or interruption (>60 day gap in continuous drug supply) were assessed using Kaplan-Meier analyses. Drug wastage cost was estimated based on overlapping days between two prescription fills: the last original dose fill and the first reduced dose fill. RESULTS: 1,242 patients initiated palbociclib-based therapy (mean age = 62.7 years, median follow-up = 8.7 months). During the 12-month post-index period, across the first four lines, dose reduction rates were 31.9-33.7% and dose reduction/interruption rates were 63.5-80.9%. A total of 411 (33.1%) patients changed dose, among whom 128 (31.1%) experienced prescription fill overlap (average = 11.1 days). Mean potential drug wastage cost among patients with fill overlap was $5,471. CONCLUSIONS: Most patients receiving palbociclib experienced dose reduction or interruption early in treatment; the associated drug wastage may lead to considerable costs.
Entities:
Keywords:
Costs; HR+/HER2-; dosing patterns; drug wastage; metastatic breast cancer; palbociclib; real-world
Authors: Claire C Conley; McKenzie McIntyre; Nicole A Pensak; Filipa Lynce; Deena Graham; Roohi Ismail-Khan; Katherine Lopez; Susan T Vadaparampil; Suzanne C O'Neill Journal: Breast Cancer Res Treat Date: 2022-01-07 Impact factor: 4.872
Authors: Emily Nash Smyth; Julie Beyrer; Kimberly R Saverno; Elizabeth Hadden; Hamed Abedtash; Angelo DeLuca; Garreth W Lawrence; Sarah Rybowski Journal: Drugs Real World Outcomes Date: 2022-09-12
Authors: Anna Maria Buehler; Gabriela Castilho; Pierre-Alexandre Dionne; Stephen Stefani Journal: Ther Adv Med Oncol Date: 2021-04-16 Impact factor: 8.168
Authors: B Porte; M Carton; F Lerebours; E Brain; D Loirat; L Haroun; A Bellesoeur; S Bach Hamba; Y Kirova; P Cottu Journal: Breast Date: 2020-11-13 Impact factor: 4.380